Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13618163 | 1.00 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL1134499 | 1.00 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL9833337 | 0.91 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL26117694 | 0.88 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL3882849 | 0.84 | MEN1 (0.55) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL9831080 | 0.83 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL24837806 | 0.83 | TP53 (0.44) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL2372673 | 0.83 | MEN1 (0.57) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL8301383 | 0.83 | MEN1 (0.57) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL28443081 | 0.81 | MAPT (0.50) | ALDH1A1MEN1KMT2AMAPTCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102083812-A | Muscarinic receptor agonits useful in the treatment of pain, alzheimer's disease and schizophrenia | ASTRAZENECA AB | 2011-06-01 | — | — | CN | disclosed |
| EP-2285798-A1 | MUSCARINIC RECEPTOR AGONITS USEFUL IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | AstraZeneca AB (SE) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009136850-A1 | MUSCARINIC RECEPTOR AGONITS USEFUL IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | WO | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | CACNA1A, SCN10A, OPRM1 | ALDH1A1 2206/4885MEN1 1884/4885KMT2A 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.